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ABSTRACT
Objective: Using data in real-world clinical practice, this
study aims to compare the health-care use patterns of patients
with schizophrenia who use oral antipsychotics.
Methods: A total of 219,504 episodes of antipsychotic drug
therapy initiated during the period from 2000 to 2002 were
identiﬁed using data from the California Medicaid program.
Four types of episodes were analyzed based on the patient’s
drug use history as far back as 1994: restarting therapy after
a break in therapy using the same drug used in the preceding
episode; switching therapy after a break in treatment using a
different medication; switching therapy without a break in
therapy; and augmentation. Health-care use patterns over a
1-year post-treatment period were analyzed using ordinary
least squares (OLS) regressions, Cox proportional hazards
models, and logistic regression.
Results: The impact of atypical antipsychotics on health-care
use in the ﬁrst post-treatment year varies by episode type.
Patients switching to atypical medications generally cost
signiﬁcantly more than similar patients switching to a
conventional antipsychotic. Olanzapine and risperidone,
however, were associated with reductions in total costs rela-
tive to conventional antipsychotics when used in restart and
augmentation episodes. Differences across all three second-
generation antipsychotics were relatively small.
Conclusions: Small differences across the atypical antipsy-
chotics suggest that these drugs are interchangeable, raising
the question of whether drug costs could be reduced through
selectively contracting for a preferred drug. Potential savings
may be limited by several factors. First, most episodes of
treatment are restart episodes. Switching these patients to a
preferred drug may have clinical risk. Second, patients with
schizophrenia switch and augment therapies frequently, thus
quickly reducing the population of patients who could be
effectively treated with a single preferred drug.
Keywords: atypical antipsychotic drugs, direct health-care
costs.
Introduction
Atypical antipsychotics are widely accepted as a ﬁrst-
line therapy for patients with schizophrenia. The use of
atypical antipsychotics, however, is coming under
increased scrutiny as the cost of these medications has
strain the budgets of health systems, especially state
Medicaid programs [1]. For example, the California
Medicaid Program (Medi-Cal) established open access
to atypical antipsychotics in October 1997, and these
medications quickly became the most costly class of
medications in terms of total expenditure [2]. Studies
comparing direct health-care costs across alternative
antipsychotic medications using real-world data are
especially critical now that many of the chronically
mentally ill are being shifted from state Medicaid drug
coverage to coverage under Medicare Part D. In
particular, Medicare Part D plans may be tempted to
control the cost of antipsychotic medications using
proven cost containment strategies, such as selectively
contracting for one or two preferred agents from a
growing list of newer products. Clearly, much more
data are needed to determine the long-term effects of
alternative second-generation antipsychotic drugs on
the total cost of treating patients with schizophrenia
before access to these medications is restricted.
The objective of this article is to compare the cost of
treating patients with schizophrenia across conven-
tional and atypical antipsychotic medications. Paid
claims data from the Medi-Cal program for the period
between January 2000 and December 2003 were used
to identify the variety of drug treatment episodes that
reﬂect the range of clinical decisions that confront
physicians treating patients with schizophrenia. Sepa-
rate analyses of total direct cost and cost by type of
service were conducted for each of four episode types:
patients restarting therapy; patients switching thera-
pies after a break in treatment; patients switching
drugs with no gap in treatment; and patients augment-
ing an existing treatment.
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Methods
Data
Data for this study were derived from a 100%-sample
of the paid claims data from the fee-for-service portion
of the Medi-Cal program for patients treated for
schizophrenia during the period from 1994 to 2003.
Patients were eligible for inclusion in the study if they
had a diagnosis of schizophrenia recorded on a paid
claim (International Classiﬁcation of Diseases, Ninth
Revision code 295.xx) and ﬁlled at least one prescrip-
tion for an antipsychotic medication during the period
(see Appendix). Summary cost data were created for
each month before and after the patient’s ﬁrst observed
treatment attempt using an antipsychotic medication.
Costs were broken down by type of service based on
data on provider type and physician specialty for phy-
sician services. Cost categories include ambulatory
care, acute hospital services, psychiatric hospital ser-
vices including services provided in psychiatric services
in acute hospitals, community mental-health center
services, prescription drugs, and all other services.
Unit of Analysis
The unit of analysis was the 12-month period following
each episode of antipsychotic drug therapy. This
approach mimics the unit of analysis found in random-
ized clinical trials, which specify a ﬁxed post-treatment
observation period and allows the analysis to compare
across alternative medications at the point of the treat-
ment decision.What is unique here is that the treatment
history of the patient is used to deﬁne ﬁve different types
of treatment episodes. Treatment history data are criti-
cal for controlling treatment selection bias because the
pattern of use across alternative antipsychotics and
post-treatment costs may differ signiﬁcantly based on
whether or not the patient is using the medication for
the ﬁrst time, switching medications, or using an antip-
sychotic as an augmentation therapy.
Five types of treatment episodes were deﬁned, four
of which were included in this analysis. These deﬁni-
tions of episode types depend critically on a determi-
nation of when a patient has interrupted drug therapy.
Breaks in treatment were deﬁned when a gap in drug
therapy longer than 15 days was observed based on
days supply and reﬁll dates for all antipsychotic medi-
cations used by the patient. The 15-day gap was
selected after consultation with the Medi-Cal program
and is consistent with the ﬁndings of Weiden et al. [3]
that the risk of hospitalization increased signiﬁcantly
in patients with schizophrenia after breaks in therapy
as short as 10 days. Any use of resources during any
period of time that a patient was off active drug
therapy was associated with an episode of drug
therapy so long as these gaps in treatment occurred
within the episode’s 12-month post-treatment period.
The ﬁve types of episodes deﬁned were as follows:
First observed episode. By deﬁnition, each patient has
one “ﬁrst” episode of antipsychotic drug therapy. Nev-
ertheless, even using 10 years of data, it is impossible to
determine whether or not the ﬁrst observed episode for
a patient during the data period was truly the ﬁrst time
the patient used an antipsychotic medication. This
problem of data truncation is even more problematic in
a Medicaid database, which likely includes patients
with schizophrenia who qualiﬁed for Medicaid cover-
age because of a disease-related disability. Given the
uncertainty of the patients’ treatment history before
their ﬁrst observed Medicaid episode, these episodes
were excluded from analysis once theywere created and
used to classify each of the subsequent antipsychotic
treatment episodes initiated by the patient.
Restart episodes using the same medication. A restart
episode is one in which a patient was not on active
antipsychotic drug therapy and initiated therapy with
the medication used in his or her most recent prior
treatment attempt.
Delayed switches in drug therapy. A delayed switching
episode is one in which a patient changed therapy from
the drugs used in his or her most recent prior treatment
attempt, but after a break in therapy.
Switching episodes. A switching episode is one in
which a patient changed medication while still on
active therapy or within 15 days of terminating a pre-
vious therapy, and discontinued use of all previous
medications within 60 days.
Augmentation episodes. An augmentation episode is
one in which a patient changed therapies without a
break in therapy and continued to purchase one ormore
of his or her previous medications beyond 60 days. The
maximum 60-day limit on concomitant use of an added
medication to differentiate between switching and aug-
mentation episodes was selected after consultation with
the Medi-Cal program and is consistent with methods
used in their analytic research.
The analyses of 12-month, post-treatment costs
across alternative second-generation antipsychotics
were conducted by episode type. This approach has
several advantages. First, separate analyses provide
more complete and relevant information for clinicians,
who must select between alternative therapies across a
wide range of clinical situations. Second, treatment
costs are likely to differ signiﬁcantly by type of episode.
For example, a patient restarting or switching thera-
pies after a break in treatment may be doing so after a
relapse in symptoms, whereas a patient switching or
augmenting treatment with no break in therapy may
be less likely to be experiencing a relapse in symptoms.
Previous research largely ignored restarting, switching,
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and augmentation episodes or mixed episode types
into a single sample, thus creating a potential bias
against medications used more frequently in higher
cost episode types. Third, any cost associated with
changes in antipsychotic therapy that occurred within
the 12-month post-treatment period were attributed
to the initial medication used, which is consistent with
the intent-to-treat standard applied in randomized
clinical trials. That is, the costs associated with future
changes in therapy were attributed to the initial drug
used in the treatment episode if these changes occur
within the 12-month post-treatment period. This
approach has been used previously in research com-
paring antidepressant medications in which the rate
of switching medications differed signiﬁcantly across
drugs [4]. Finally, conducting the analysis separately
by episode type helps disentangle the overlapping epi-
sodes created by using a ﬁxed post-treatment period.
To facilitate the processing of several million paid
claims records, cost data were allocated to 30-day
periods based on the date of the patient’s ﬁrst observed
use of antipsychotic drug therapy. As a result, the
differentiation between the pre- and post-treatment
periods based on the exact day a new episode was
initiated was not feasible. Instead, the month in which
an episode of therapy was initiated was designated as
the “switch” month for the episode and was consid-
ered part of the pretreatment period. This was carried
out to assure that the costs of any institutional care
preceding the initiation of treatment was not allocated
to the post-treatment period or attributed to the initial
drug used in the episode. Two additional periods were
then deﬁned around the switch month: a 6-month
pretreatment period and the 1-year post-treatment
period. Eligibility data were not available from Medi-
Cal. Therefore, to conﬁrm patient eligibility during the
entire 19 months covered by each episode observation,
the patient had to have used services before and after
the 19-month episode period.
Many Medi-Cal patients with severe mental disor-
ders are dually eligible for both Medicare and Medic-
aid, with Medicare assuming ﬁscal responsibility as
ﬁrst payer. Moreover, dropping these patients from the
analysis would exclude the majority of the patients
treated for schizophrenia. Therefore, methods of esti-
mating missing Medicare payments were developed.
Ambulatory service (Part B) payment data were esti-
mated for dually eligible patients using the amount
paid by Medicaid and the Medicare Part B deductible
and coinsurance rate. First, the total amount paid by
Medicaid for Part B-covered services, including ser-
vices provided and billed by county mental-health
systems, was totaled across services and across the
months included in the pre- and post-treatment
periods. Next, the Part B deductible amount for each
period was subtracted to approximate the amount of
the Medicaid payments that corresponded to the
Medicare coinsurance liability. If the estimated coin-
surance liability was greater than zero, it was then
multiplied by a factor of 5 to re-inﬂate the estimated
coinsurance liability to an estimate of the total pay-
ments allowed by Medicare and the deductible was
re-added. If the estimated coinsurance liability was
zero or negative, the actual amount paid by Medicaid
was used as the estimate of total Part B payments.
Although this methodology has been used previously
for Medi-Cal patients with schizophrenia [5], its appli-
cation to only dually eligible patients could either over-
or underestimate ambulatory care payments for these
patients. This could introduce an unknown bias if
alternative antipsychotics are used differentially in
treating dually eligible patients.
Total cost for institutional care was estimated for all
patients using per-diem cost estimates and days of
service as reported on hospital and nursing home paid
claims. Hospital days were assigned a cost of $1032
[6] while nursing home costs per day were valued at
$270 [7].
Units of observation were created for all episodes of
drug therapy initiated by Medi-Cal patients during the
entire data period from 1994 to 2003. Episodes of
drug therapy initiated after January 1, 2000 were then
selected to ensure that the rapid but temporary inﬂux
of patients restarting drug therapy associated with the
expansion of the Medi-Cal formulary in October 1997
to include atypical antipsychotics had stabilized [5].
This restriction also avoids the early quetiapine epi-
sodes as it received Food and Drug Administration
(FDA) approval in the fall of 1997. Finally, episodes of
care initiated with either ziprasidone or clozapine were
excluded from this analysis because of the limited
sample size and the late availability of ziprasidone
during the study period.
Statistical Methods
Logistic regression models were estimated for dichoto-
mous outcome variables indicating the use of acute
hospital, psychiatric hospital or nursing home care, or
a suicide attempt during the ﬁrst treatment year. Cox
proportional hazards models were estimated based on
the time to each of these events or until the last day of
available data for the patient. Finally, OLS regressions
were estimated for actual costs and the log of cost by
type of service because the study inclusion and exclu-
sion criteria resulted in virtually all episodes having
positive post-treatment cost.
The presence of multiple episodes for most patients
violates the assumption of independence across obser-
vations. Under these conditions, the regression estima-
tors continue to be unbiased; however, the estimated
standard errors are biased. Statistical estimation tech-
niques were used to adjust estimated standard errors
for clustering of episode observations by patient [8]
using STATA (StataCorp., College Station, TX).
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Independent Variables
The development of an exhaustive list of independent
variables for inclusion in the multivariate statistical
models is the ﬁrst line of defense against treatment
selection bias in nonrandomized studies that compare
patient outcomes and costs across alternative treat-
ment options. This study has developed independent
variables related to patient demographics, medical and
mental-health diagnostic proﬁle of the patient, and
prior use of health-care services by type of service.
Information related to the patient’s prior use of antip-
sychotic medications included 1) a dichotomous vari-
able indicating that two or more medications were
used as initial therapy; 2) a dichotomous variable indi-
cating whether the treatment selection decision consti-
tuted a change in class of antipsychotic medication
(conventional or second-generation) relative to medi-
cations used in the prior 6 months; 3) the duration of
therapy achieved during the patient’s previous episode
of therapy; and 4) the number of days between epi-
sodes (restart and delayed switching episodes).
Results
Baseline Patient Characteristics
The data on selected baseline characteristics of the
study sample by episode type and drug are presented in
Table 1. Two important ﬁndings support the decision
to conduct the following analyses separately by
episode type. First, the baseline characteristics of the
patient sample changes signiﬁcantly by episode type.
For example, patients initiating an episode of augmen-
tation therapy are more likely to be male, white, have
a disability, and more costly to treat in the prior
6 months than patients restarting a drug used previ-
ously. More importantly, however, patients restarting
therapy using the same medication as before exhibit a
signiﬁcantly lower cost in the 6 months before the start
of treatment ($5454 to $8715) than patients switching
treatments with no break in therapy ($10,007 to
$11,178) or patients augmenting therapy ($10,209 to
$14,558). Second, the distributions of episode types
are quite different across drugs. For example, 61.5%
of olanzapine episodes and 57.6% of risperidone epi-
sodes are initiated by patients who used these drugs in
their most recent treatment attempt (restart episodes).
Only 38.8% of all quetiapine episodes and 43.8% of
all episodes using typical antipsychotics are restart epi-
sodes. Therefore, previous research that aggregated
different episode types into a single analysis may have
resulted in biased comparisons of post-treatment cost
across drugs. To avoid repeating these biases, separate
analyses were conducted for each type of episode.
Descriptive Statistics: Utilization of Services and Costs
by Type of Service
The descriptive statistics describing the drug therapy
outcomes achieved by patients using atypical and
Table 1 Baseline patient characteristics by drug and type of episode
Medication use pattern
Olanzapine
N = 65,844
Risperidone
N = 52,861
Quetiapine
N = 27,141
Typicals
N = 67,163
Restart episodes using same medication N = 40,510
(61.5%)
N = 30,469
(57.6%)
N = 10,385
(38.3%)
N = 29,422
(43.8%)
Age (in years) 42.5 43.5 42.0 46.3
White race (%) 45.9 45.1 50.0 45.2
Male (%) 55.0 48.7 46.2 50.3
Disabled (%) 75.6 74.4 74.3 84.1
Health-care cost ($/prior 6 months) 6,674 6,677 7,930 5,454
Delayed switching episodes N = 11,459
(17.4%)
N = 9,483
(17.9%)
N = 6,407
(23.6%)
N = 11,176
(16.6%)
Age (in years) 42.6 42.8 41.8 42.7
White race (%) 47.7 46.7 48.7 46.7
Male (%) 54.2 50.1 50.1 51.7
Disabled (%) 77.3 75.6 75.6 79.8
Health-care cost ($/prior 6 months) 8,328 8,315 8,355 9,631
Switching episodes N = 7,694
(11.7%)
N = 6,761
(12.8%)
N = 5,258
(19.4%)
N = 7,055
(10.5%)
Age (in years) 43.1 43.3 42.8 43.0
White race (%) 52.7 52.0 54.5 51.1
Male (%) 52.5 49.8 47.9 50.6
Disabled (%) 80.2 79.7 78.1 82.2
Health-care cost ($/prior 6 months) 10,076 10,353 10,149 11,178
Augmentation episodes N = 6,181
(9.4%)
N = 6,148
(11.6%)
N = 5,091
(18.8%)
N = 19,510
(29.0%)
Age (in years) 42.9 42.8 42.1 43.7
White race (%) 53.3 53.4 54.3 56.3
Male (%) 58.2 54.5 53.9 54.7
Disabled (%) 83.2 83.6 82.4 84.1
Health-care cost ($/prior 6 months) 10,209 10,767 10,472 14,558
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typical antipsychotic medications are presented in
Table 2. The pattern of unadjusted health-care utiliza-
tion outcomes varies signiﬁcantly across episode types,
which further justiﬁes conducting the cost analysis
separately by type of episode. Nevertheless, the reasons
why post-treatment costs vary by episode type are not
the focus of this analysis comparing costs across drugs.
The data in Table 2 suggest that unadjusted differences
in post-treatment costs across drugs were often small:
Restart episodes. Patients restarting therapy using
olanzapine achieve lower unadjusted net cost relative
Table 2 Unadjusted health-care use and cost patterns by drug and type of episode
Use of health care: 1 year post (%) Olanzapine Risperidone Quetiapine Typicals
Restart episodes using same medication N = 40,510 N = 30,469 N = 10,385 N = 29,422
Acute admission 7.05 6.88 9.09 7.97
Psychiatric admission 9.86 8.92 11.82 7.99
Nursing home 4.33 6.25 4.84 5.96
Attempted suicide 6.35 5.40 9.21 4.84
Cost by type of service ($/year)
Ambulatory care 1,407 1,375 1,821 1,737
Drugs 5,801 4,736 6,722 2,999
Acute hospital 430 465 531 642
Psychiatric hospital 1,140 931 1,366 1,081
Nursing home 2,400 3,833 2,502 3,791
Community mental-health center 3,115 2,918 4,006 1,995
All other services 252 279 264 308
Net cost (total-drug) 8,746 9,800 10,489 9,555
Total 14,547 14,537 17,211 12,554
Delayed switching episodes N = 11,459 N = 9,483 N = 6,407 N = 11,176
Acute admission 8.14 8.41 9.24 9.90
Psychiatric admission 13.73 12.81 13.72 14.32
Nursing home 6.91 7.96 6.60 8.18
Attempted suicide 9.16 9.26 10.38 9.31
Cost by type of service ($/year)
Ambulatory care 1,547 1,682 1,799 1,791
Drugs 6,422 5,835 6,987 5,170
Acute hospital 529 573 581 701
Psychiatric hospital 1,807 1,490 1,643 1,897
Nursing home 3,550 4,367 3,257 4,542
Community mental-health center 3,739 3,869 4,298 3,622
All other services 279 298 249 269
Net cost (total-drug) 11,451 12,278 11,826 12,822
Total 17,874 18,113 18,813 17,991
Switching episodes N = 7,694 N = 6,761 N = 5,258 N = 7,055
Acute admission 9.14 9.53 9.15 9.96
Psychiatric admission 13.09 13.15 14.36 14.80
Nursing home 9.51 10.86 8.65 10.52
Attempted suicide 10.40 10.28 12.59 10.90
Cost by type of service ($/year)
Ambulatory care 1,937 1,818 1,954 2,105
Drugs 7,470 6,516 7,455 6,168
Acute hospital 576 736 563 697
Psychiatric hospital 1,947 1,639 18,480 1,921
Nursing home 5,538 6,456 4,648 6,038
Community mental-health center 4,093 4,127 4,831 4,276
All other services 328 342 322 311
Net cost (total-drug) 14,419 15,119 14,165 15,348
Total 21,889 21,635 21,620 21,516
Augmentation episodes N = 6,181 N = 6,148 N = 5,091 N = 19,510
Acute admission 7.57 6.99 8.05 8.83
Psychiatric admission 9.43 9.29 10.29 11.13
Nursing Home 9.11 9.52 7.62 17.15
Attempted suicide 7.44 8.08 8.43 8.46
Cost by type of service ($/year)
Ambulatory care 1,784 1,765 1,685 2,062
Drugs 8,959 9,050 9,709 9,067
Acute hospital 503 445 547 663
Psychiatric hospital 1,181 1,132 1,105 1,872
Nursing home 5,234 57,155 4,583 11,160
Community mental-health center 3,974 4,278 4,547 4,201
All other services 349 265 324 331
Net cost (total-drug) 13,026 13,700 12,792 20,289
Total 21,985 22,751 22,500 29,356
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to other medications, primarily because oﬂower use
of nursing home care. Once drug costs are added,
however, patients restarting on the same typical antip-
sychotic used previously have the lowest unadjusted
total costs. Quetiapine patients exhibit the highest
rates of unadjusted net and total costs.
Delayed switching episodes. The unadjusted results
for net costs for patients switching drugs after a break
in therapy also favor olanzapine, while patients
switching to a typical antipsychotic have the highest
unadjusted net costs. Quetiapine patients exhibit the
highest total unadjusted cost, although the difference
across all drugs is less than $1000/year.
Switching episodes. Patients switching to olanzapine
have the highest unadjusted total cost, while patients
switching to a typical antipsychotic without a break
have the highest unadjusted net cost and lowest total
cost. Again, the differences in unadjusted cost across
drugs are small.
Augmentation episodes. Patients augmenting their
current therapy using a typical antipsychotic have the
highest unadjusted net and total costs. Unlike other
episode types, the differences in total costs across drugs
were nearly $7400/year.
These differences in the relative performance across
antipsychotics by episode type further underscore the
importance of making heal-to-head comparisons by
episode type.
Multivariate Results
The results of the various multivariate analyses of
health-care use and costs across drugs are presented in
Tables 3–6. Each atypical antipsychotic, olanzapine,
risperidone, and quetiapine, is compared with patients
using typical antipsychotics.
Restart episodes. Restart episodes constitute more
than half of all treatment episodes for antipsychotic
drug therapy by patients with schizophrenia. In
general, patients restarting treatment using olanzapine
and risperidone appear to utilize health-care services
signiﬁcantly less than patients restarting therapy using
a typical antipsychotic (Table 3). Not surprisingly,
drug costs are signiﬁcantly higher for patients using
atypical antipsychotics, but these increased costs are
offset by lower costs for all other types of medical care
in the models using costs measured in dollars per year.
Nevertheless, the analyses based on the log transfor-
mation of total costs indicate signiﬁcantly higher costs
across all three second-generation antipsychotics. The
results for the impact of atypical antipsychotics on the
Table 3 Estimated impacts of atypical antipsychotics on health-care use and cost patterns: restart episodes using same medication
Type of service Olanzapine Risperidone Quetiapine Combo therapy Changed Class Adjusted R2
Log transformed costs (%)
Ambulatory serviced -39.2‡ -32.5‡ -18.3‡ NA 19.2‡ 0.2820
Community mental-health center 2.9 7.2 13.3* NA 7.2* 0.2824
Psychiatric hospital -6.4† -9.6‡ 2.7 NA 12.1*** 0.2171
Acute hospital -7.9† -9.3‡ -4.5 NA 3.4 0.1226
Nursing home -9.3‡ -2.3 -5.5* NA 4.8* 0.5979
Other services -13.4‡ -11.1‡ -0.3 NA 10.2‡ 0.1471
Net costs (Total-Rx) -32.0‡ -22.0‡ -15.4‡ NA 13.0‡ 0.3306
Prescription drugs 67.8‡ 51.4‡ 58.7‡ NA 13.6‡ 0.2729
Total costs 20.4‡ 15.3‡ 23.5‡ NA 14.0‡ 0.4304
Actual costs ($/year)
Ambulatory serviced -551‡ -532‡ -388‡ NA 185† 0.1007
Community mental-health center -447‡ -262‡ 217* NA 398‡ 0.1609
Psychiatric hospital -591† -630‡ -452* NA 52 0.0823
Acute hospital -195† -167* -197† NA 21 0.0643
Nursing home -868‡ -411‡ -727‡ NA 39 0.6624
Other services -72* -55* -99† NA 12 0.0307
Net costs (Total-Rx) -2725‡ -2057‡ -1648‡ NA 708‡ 0.4587
Prescription drugs 1901‡ 965‡ 2158‡ NA 568‡ 0.2234
Total costs -824† -1092‡ 510 NA 1276‡ 0.4618
Logistic odds ratios
Acute hospital 0.86† 0.84‡ 0.97 0.97 1.09* 0.1340
Psychiatric hospital 0.97 0.89* 1.13* 0.92 1.23‡ 0.1849
Nursing home 0.83* 0.98 0.98 1.12 1.33‡ 0.3657
Attempted suicide 1.02 0.93 1.24† 0.97 1.33‡ 0.1263
Cox proportions hazard ratios
Acute hospital 1.00 0.96 1.22‡ 0.94 1.21‡
Psychiatric hospital 1.00 0.90** 1.12* 0.98 1.16‡
Nursing home 0.88* 0.94 0.90 0.93 1.19†
Attempted suicide 1.09 0.96 1.27‡ 0.91 1.25‡
*P < 0.05; †P < 0.01; ‡P < 0.001.
Number of episodes of treatment = 106,728. Number of individual patients = 46,836.
NA, not applicable.
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use of institutional care and attempted suicides
support the models using actual costs because olanza-
pine and risperidone are associated with reduced risk
for institutionalization. The inconsistencies between
the results for actual and log transformed costs may be
due to the devaluing of outlier values (i.e., hospitalized
patients) in the log transform cost models. The results
from the actual cost models for quetiapine indicate
savings in net costs, but these results are not well
supported by the logistic and cost model results for the
likelihood of institutionalization or suicide attempts.
Switching episodes. The multivariate results for
switching episodes are presented in Table 4 (delayed
switch) and Table 5 (switches with no break). The
increased drug costs associated with the use of atypical
antipsychotics are not offset by signiﬁcant reductions
in the use of medical care over the 1-year period after
the switch in drugs. At best, patients switching to
risperidone were not statistically different from
patients switching to a conventional antipsychotic,
although both estimated log transform and actual cost
effects indicate higher costs.
Augmentation episodes. Finally, the multivariate
models for augmentation episodes are presented in
Table 6. Atypical antipsychotic medications appear to
be either cost-neutral (log models) or cost-saving
(actual cost models) when used as an augmentation
therapy. The uniformly higher drug costs associated
with atypical use are offset by lower costs for medical
care for all three medications, and the majority of these
savings are due to lower costs for psychiatric hospital
care and nursing home services.
Tables 3–6 also include information on the impact
on costs and health-care utilization of the patient
changing the class of antipsychotic being used (con-
ventional to atypical or vice versa) and the initiation of
combination therapy (polypharmacy). Not surpris-
ingly, patients changing the class of medication used in
the prior 6 months are uniformly more expensive and
at higher risk for suicide and institutionalization than
patients using drugs within a single class. These results
suggest that the decision to change drug class in the
short term may be correlated with several factors,
including the efﬁcacy of the drug used previously, its
side effects, and the severity of the patient’s illness.
Conversely, patients initiating a drug therapy episode
using a combination of two or more antipsychotics
were not found to be more costly or at higher risk for
hospitalization than patients initiating monotherapy
episodes. In fact, patients switching drugs after a break
in treatment who use combination therapy were at
lower risk for hospitalization and attempted suicide
than similar patients switching to a new monotherapy
(Table 4).
Table 4 Estimated impacts of atypical antipsychotics on health-care use and cost patterns: delayed switching episodes
Type of service Olanzapine Risperidone Quetiapine Combo therapy Changed class Adjusted R2
Log transformed costs (%)
Ambulatory serviced -23.2‡ -11.2‡ -3.7 -2.5 22.0‡ 0.2624
Community mental-health center 10.6* 25.5‡ 23.1‡ -4.2 11.0* 0.2492
Psychiatric hospital -4.6 -5.2 0.9 -10.0* 5.6 0.2285
Acute hospital -10.6† -12.7‡ -4.2 -8.2* 6.6* 0.1625
Nursing home 0.3 -1.0 -0.4 1.0. 12.0‡ 0.5377
Other services -3.0 -2.0 -0.2 -4.8 13.3‡ 0.1449
Net costs (Total-Rx) -7.4† -1.3 2.8 -11.3‡ 16.6‡ 0.2882
Prescription drugs 41.3‡ 25.3‡ 35.5‡ 18.8‡ 5.4† 0.1731
Total costs 15.5‡ 9.4‡ 17.3‡ 5.7† 11.0‡ 0.3036
Actual costs ($/year)
Ambulatory serviced -189† -111 -53 -49 266‡ 0.1167
Community mental-health center -144 184 187 44 209* 0.1386
Psychiatric hospital -75 -247 -76 289 67 0.0752
Acute hospital -116* -106 -95 -81 36 0.0984
Nursing home -168 -122 -221 -44 486† 0.5687
Other services 24 23 -7 -16 30 0.0495
Net costs (Total-Rx) -668* -380 -267 143 1097‡ 0.3812
Prescription drugs 1399‡ 660‡ 1432‡ 743‡ 281‡ 0.1652
Total costs 730* 281 1165† 887† 1378‡ 0.3801
Logistic odds ratios
Acute hospital 0.85† 0.83† 0.97 0.83† 1.12* 0.1579
Psychiatric hospital 0.93 0.95 1.01 0.87† 1.08 0.1965
Nursing home 1.02 0.97 1.06 1.19* 1.48‡ 0.3389
Attempted suicide 1.00 1.04 1.05 0.90* 1.09 0.1219
Cox proportional hazards ratios
Acute hospital 0.95* 0.96 1.08† 0.93† 1.13
Psychiatric hospital 0.94 0.91† 0.98 0.98 1.08*
Nursing home 0.93 1.07 1.00 0.83† 1.30
Attempted suicide 1.02 1.04 1.04 0.93* 1.06
*P < 0.05; †P < 0.01; ‡P < 0.001.
Number of episodes of treatment = 32,443. Number of individual patients = 24,105.
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Discussion
Second-generation antipsychotics were found to sig-
niﬁcantly increase drug costs over the ﬁrst post-
treatment year across all types of episodes. These
costs are not necessarily offset by reductions in the
use of other medical services. In particular, second-
generation antipsychotics do not appear to be cost-
saving relative to conventional antipsychotics for
patients switching medications, delayed or without a
break in therapy. The use of second-generation antip-
sychotics appears to be most cost-effective in patients
who restart therapy using the same medication,
which is an indication that the drug was effective in
the previous treatment attempt. Well more than half
of olanzapine and risperidone treatment episodes fall
into this category as compared with 43% of drug
therapy episodes involving a conventional antipsy-
chotic (Table 1).
Although direct comparisons across the second-
generation antipsychotics were not undertaken, the
results reported here indicate that olanzapine and ris-
peridone achieve very similar patterns of health-care
use over the ﬁrst post-treatment year. Quetiapine was
found to be somewhat less effective than its competi-
tors in terms of costs even after the analyses were
conducted separately by episode type. The marginally
poorer performance of quetiapine may be due to
underdosing, especially in early episodes, or its role as
the third product introduced into the market. For
example, McCombs, Mulani, and Gibson [5] found a
pool of untreated patients who return to attempt
therapy as new drugs are introduced. These patients
may be more difﬁcult and more costly to treat. More
research will be required to clarify these issues.
The relative equality of patient outcomes achieved
across second-generation antipsychotics does not nec-
essarily indicate that patients can be adequately
treated by a limited range of these medications being
selected as preferred products based on price or
pending generic status. California physicians are
using these medications differentially, especially in
terms of type of episode. The differential use of alter-
native atypical antipsychotics by episode type sug-
gests that each medication may have a clinical niche
in which it achieves clinically superior outcomes. If
so, delisting one or two second-generation drugs
from open formulary status runs the risk of harming
these patients. More research is needed to determine
the speciﬁc patient groups and clinical situations in
which each atypical antipsychotic is the most cost-
effective medication.
Analyses based on paid claims data have a host of
limitations that must be considered in interpreting
these results. First, data documenting potential differ-
ences in severity of illness, sensitivity to side effects,
Table 5 Estimated impacts of atypical antipsychotics on health-care use and cost patterns: switching episodes
Type of service Olanzapine Risperidone Quetiapine Combo therapy Changed class Adjusted R2
Log transformed costs
Ambulatory serviced -10.3† -3.4 -1.6 -8.8 5.1 0.2686
Community mental-health center 8.5 17.5† 21.6‡ -31.2† -3.6 0.2696
Psychiatric hospital -7.1 -5.2 9.6* 3.5 7.9* 0.2250
Acute hospital -3.5 -1.3 -5.2 -7.6 1.1 0.1401
Nursing home -1.6 3.3 5.0 8.6 5.7 0.5765
Other services -3.3 1.8 4.4 -6.1 10.4† 0.1394
Net costs (Total-Rx) 4.1 7.4* 12.1‡ -20.6‡ 3.9* 0.3414
Prescription drugs 39.6‡ 24.9‡ 30.4‡ 5.2 4.8† 0.1963
Total costs 19.0‡ 11.9‡ 18.1‡ 0.9 6.2‡ 0.4105
Actual costs
Ambulatory serviced -41 -213* -154 -21 195* 0.0721
Community mental-health center -125 31 348* -204 274† 0.1780
Psychiatric hospital 276 -15 275 -207 372* 0.0835
Acute hospital -71 57 -114 -48 40 0.0729
Nursing home -17 212 123 507 153 0.6066
Other services 19 21 13 51 19 0.0467
Net costs (Total-Rx) 43 95 490 78 1053‡ 0.4456
Prescription drugs 1531‡ 534‡ 1008‡ 592‡ 306† 0.1923
Total costs 1573‡ 629 1498‡ 670 1360‡ 0.4495
Logistic odds ratios
Acute hospital 0.94 0.98 0.94 0.87 1.02 0.1483
Psychiatric hospital 0.89* 0.94 1.12 1.07 1.10 0.1966
Nursing home 0.93 1.06 1.10 1.25 1.24† 0.3602
Attempted suicide 0.98 1.00 1.20** 0.88 1.03 0.1288
Cox proportional hazards ratios
Acute hospital 0.93* 0.93* 1.06 1.12* 1.08†
Psychiatric hospital 0.90* 0.92* 1.02 0.96 1.00
Nursing home 0.99 1.02 1.02 0.90 1.16*
Attempted suicide 0.95 0.95 1.06 0.97 0.96
*P < 0.05; †P < 0.01; ‡P < 0.001.
Number of episodes of treatment = 26,024. Number of individual patients = 17,538.
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and treatment history across alternative drugs are not
available on paid claims. For example, quetiapine was
the last of the three study atypical antipsychotics to
receive FDA approval and may have been used to treat
patients refractory to all or most other antipsychotics.
Although every effort has been made to take into
account drug treatment history in this analysis, unob-
served treatment selection bias may still have existed.
Second, patients may not maintain continuous Medi-
Cal eligibility or may receive care from other sources
of coverage, such as the VA or county health facilities.
Most of the sample in this study, however, gained
Medi-Cal eligibility because of disability status, thus
reducing the likelihood of losing eligibility but increas-
ing the likelihood of receiving care outside the Medi-
Cal system. These losses in a patient’s paid claims
history could bias study results if lost eligibility or
out-of-system use is not equally distributed across the
alternative drugs under study.
Conclusions
Two conclusions can be derived from the results of
this study. First, comparisons across antipsychotics
must take into account the treatment history of the
patient and the clinical conditions under which these
medications are being used. In this case, olanzapine
and risperidone were used to treat a different mix of
treatment episode types than quetiapine, possibly
because of the order of product availability. The cost
of treating patients varies by episode type, with
switching and augmentation episodes having the
highest post-treatment cost over 1 year. Therefore,
comparisons across drugs using aggregated samples
of patient episodes could be biased against drugs
used in switching and augmentation episodes.
Second, the atypical antipsychotics appear to gener-
ate reductions in the cost of medical services that
offset, at least partially, the higher cost of these medi-
cations. The one exception to this ﬁnding was for
patients switching therapy without a break in treat-
ment who may be the most difﬁcult group of patients
to treat but represent only 12% to 19% of all patient
episodes. Therefore, these results suggest that the sig-
niﬁcant increase in the Medi-Cal drug budget devoted
to purchasing atypical antipsychotics may not have
increased total cost of treatment for patients with
schizophrenia.
Source of ﬁnancial support: Support for this research was
provided by Eli Lilly and Company, the maker of olanzapine.
The University of Southern California retains all publication
rights subject to time-limited review and comment by Eli Lilly
and Company.
Table 6 Estimated impacts of atypical antipsychotics on health-care use and cost patterns: augmentation episodes
Type of service Olanzapine Risperidone Quetiapine Combo therapy Changed class Adjusted R2
Log transformed costs
Ambulatory serviced -14.4‡ -8.2 -1.1 8.4 7.3† 0.2658
Community mental-health center 8.6 25.3‡ 9.5 1.9 -0.7 0.2765
Psychiatric hospital -5.6 -7.9* 1.9 10.0 13.1‡ 0.1855
Acute hospital -1.9 -6.0 1.9 -12.7 -0.9 0.1354
Nursing home -11.1† -10.7† -20.2‡ -10.6 5.9 0.6456
Other services -1.6 6.0 -8.0 11.3 11.3† 0.1272
Net costs (Total-Rx) -3.6 2.2 -4.5 0.6 7.1* 0.3724
Prescription drugs 2.9 3.7* 8.3‡ 4.6 2.2 0.2219
Total costs -0.3 1.3 2.6 0.5 1.7 0.4740
Actual costs
Ambulatory serviced 5 -61 -203 -158 -151 0.0662
Community health center -72 129 97 -118 -55 0.1738
Psychiatric hospital -348* -419** -366* -780 177 0.0718
Acute hospital -63 -113* -25 -85 -48 0.0838
Nursing home -706† -617† -983‡ -812 87 0.6736
Other services 52 54 13 -1 10 0.0410
Net costs (Total-Rx) -1132‡ -1025† -1465‡ -393 20 0.5244
Prescription drugs 321† 282† 425‡ -90* -29 0.2400
Total costs -810* -744* -1040† -484 -9 0.5283
Logistic odds ratios
Acute hospital 0.96 0.87 1.05 0.78 1.00 0.1551
Psychiatric hospital 0.93 0.92 1.11 1.11 1.23‡ 0.1744
Nursing home 0.81* 0.79† 0.60‡ 0.80 1.17* 0.3947
Attempted suicide 0.97 1.06 1.03 0.86 1.01 0.1198
Cox proportional hazards ratios
Acute hospital 0.94* 0.95 1.00 1.01 1.02
Psychiatric hospital 0.96 0.97 1.07 1.11 1.21‡
Nursing home 0.86* 0.94 0.80† 0.92 1.15*
Attempted suicide 1.01 0.99 1.00 1.01 1.04
*P < 0.05; †P < 0.01; ‡P < 0.001.
Number of episodes of treatment = 36,421. Number of individual patients = 19,959.
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Appendix
Antipsychotics
Conventional Second-generation
Chlorpromazine Clozapine
Fluphenazine (regular or depot) Olanzapine
Haloperidol (regular or depot) Risperidone
Loxapine Quetiapine
Molindone Ziprasidone
Perphenazine
Pimozide
Prochlorperazine
Serentil
Thiothixene
Thioridazine
Triﬂuoperazine
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